• Japanese
  • Korean
  • Chinese
Cover Image

Oncology Partnering Terms and Agreements

The Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in oncology partnering deals
  • Average deal terms for headline, upfront and royalty by stage of development
  • Oncology partnering agreement structure
  • Oncology partnering contract documents
  • Top oncology deals by value
  • Most active oncology dealmakers

The Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 2,700 links to online copies of actual oncology deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in oncology dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading oncology deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of oncology partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), technology type and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in oncology partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of oncology technologies and products.

Report scope

Oncology Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to oncology trends and structure of deals entered into by leading companies worldwide.

Oncology Partnering Terms and Agreements includes:

  • Trends in oncology dealmaking in the biopharma industry since 2009
  • Analysis of oncology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life oncology deals
  • Access to over 2,700 oncology contract documents
  • The leading oncology deals by value since 2009
  • Most active oncology dealmakers since 2009
  • The leading oncology partnering resources

In Oncology Partnering Terms and Agreements, the available contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Oncology Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 2,700 oncology deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise oncology rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Oncology Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of oncology deal trends since 2009
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 2,700 actual oncology contracts entered into by the world's biopharma companies
  • Detailed access to actual oncology contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a oncology agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in oncology dealmaking

  • 2.1. Introduction
  • 2.2. Oncology partnering over the years
  • 2.3. Big pharma oncology dealmaking activity
  • 2.4. Big biotech oncology dealmaking activity
  • 2.5. Most active in oncology partnering
  • 2.6. Oncology partnering by deal type
  • 2.7. Oncology partnering by industry sector
  • 2.8. Oncology partnering by stage of development
  • 2.9. Oncology partnering by technology type
  • 2.10. Oncology partnering by oncology indication
  • 2.11. Average deal terms for oncology
    • 2.11.1 Oncology headline values
    • 2.11.2 Oncology upfront payments
    • 2.11.3 Oncology milestone payments
    • 2.11.4 Oncology royalty rates

Chapter 3 - Leading oncology deals

  • 3.1. Introduction
  • 3.2. Top oncology deals by value

Chapter 4 - Bigpharma oncology deals

  • 4.1. Introduction
  • 4.2. How to use bigpharma partnering deals
  • 4.3. Bigpharma oncology partnering company profiles
    • Abbott
    • Actavis
    • Allergan
    • Amgen
    • Astellas
    • AstraZeneca
    • Baxter International
    • Bayer
    • Biogen Idec
    • Boehringer Ingelheim
    • Bristol-Myers Squibb
    • Celgene
    • CSL
    • Daiichi Sankyo
    • Dainippon Sumitomo
    • Eisai
    • Eli Lilly
    • Endo Pharmaceuticals
    • Fresenius
    • Galderma
    • Gilead Sciences
    • GlaxoSmithKline
    • Grifols
    • Hospira
    • Johnson & Johnson
    • Kyowa Hakko Kirin
    • Lundbeck
    • Menarini
    • Merck & Co
    • Merck KGaA
    • Mitsubishi Tanabe
    • Mylan
    • Novartis
    • Novo Nordisk
    • Otsuka
    • Pfizer
    • Purdue
    • Ranbaxy Laboratories
    • Roche
    • Roche
    • Sanofi
    • Servier
    • Takeda
    • Teva
    • Teva Pharmaceuticals
    • UCB
    • Valeant

Chapter 5 - Big biotech oncology deals

  • 5.1. Introduction
  • 5.2. How to use big biotech partnering deals
  • 5.3. Big biotech oncology partnering company profiles
    • 3SBio
    • Actelion
    • Alexion Pharmaceuticals
    • AMAG Pharmaceuticals
    • Array Biopharma
    • Bavarian Nordic
    • Biocon
    • Biogen Idec
    • BioMarin Pharmaceuticals
    • Cangene
    • Dendreon
    • Elan
    • Emergent BioSolutions
    • Enzo Biochem
    • Galapagos
    • Genmab
    • Ipsen
    • Isis Pharmaceuticals
    • LFB Group
    • Medivation
    • Morphosys
    • Nektar Therapeutics
    • Novo Nordisk
    • Onyx Pharmaceuticals
    • Optimer
    • PDL BioPharma
    • Regeneron Pharmaceuticals
    • Sciclone Pharmaceuticals
    • Seattle Genetics
    • Spectrum Pharmaceuticals
    • Swedish Orphan Biovitrum

Table of figures

  • Figure 1: Oncology partnering since 2009
  • Figure 2: Big pharma - top 50 - Oncology deals 2009-2014
  • Figure 3: Bigpharma oncology deal frequency - 2009-2014
  • Figure 4: Big biotech - top 50 - Oncology deals 2009-2014
  • Figure 5: Big biotech oncology deal frequency - 2009-2014
  • Figure 6: Active oncology dealmaking activity- 2009-2014
  • Figure 7: Oncology partnering by deal type since 2009
  • Figure 8: Oncology partnering by industry sector since 2009
  • Figure 9: Oncology partnering by stage of development since 2009
  • Figure 10: Oncology partnering by technology type since 2009
  • Figure 11: Oncology partnering by oncology target since 2009
  • Figure 12: Oncology deals with a headline value
  • Figure 13: Oncology deal headline value distribution, US$million - discovery stage
  • Figure 14: Oncology deal headline value distribution, US$million - preclinical stage
  • Figure 15: Oncology deal headline value distribution, US$million - phase I stage
  • Figure 16: Oncology deal headline value distribution, US$million - phase II stage
  • Figure 17: Oncology deal headline value distribution, US$million - phase III stage
  • Figure 18: Oncology deal headline value distribution, US$million - regulatory stage
  • Figure 19: Oncology deal headline value distribution, US$million - marketed stage
  • Figure 20: Summary median headline value by stage of development, 2009-2014
  • Figure 21 Oncology deals with upfront payment values
  • Figure 22: Oncology deal upfront payment distribution, US$million - discovery stage
  • Figure 23: Oncology deal upfront payment distribution, US$million - preclinical stage
  • Figure 24: Oncology deal upfront payment distribution, US$million - phase I stage
  • Figure 25: Oncology deal upfront payment distribution, US$million - phase II stage
  • Figure 26: Oncology deal upfront payment distribution, US$million - phase III stage
  • Figure 27: Oncology deal upfront payment distribution, US$million - regulatory stage
  • Figure 28: Oncology deal upfront payment distribution, US$million - marketed stage
  • Figure 29: Summary median upfront payments by stage of development, 2009-2014
  • Figure 30: Oncology deals with milestone payments
  • Figure 31: Oncology deal milestone distribution, US$million - discovery stage
  • Figure 32: Oncology deal milestone distribution, US$million - preclinical stage
  • Figure 33: Oncology deal milestone distribution, US$million - phase I stage
  • Figure 34: Oncology deal milestone distribution, US$million - phase II stage
  • Figure 35: Oncology deal milestone distribution, US$million - phase III stage
  • Figure 36: Oncology deal milestone distribution, US$million - regulatory stage
  • Figure 37: Oncology deal milestone distribution, US$million - marketed stage
  • Figure 38: Oncology deals with royalty rates, %
  • Figure 39: Oncology deal royalty rate distribution, US$million - discovery stage
  • Figure 40: Oncology deal royalty rate distribution, US$million - preclinical stage
  • Figure 41: Oncology deal royalty rate distribution, US$million - phase I stage
  • Figure 42: Oncology deal royalty rate distribution, US$million - phase II stage
  • Figure 43: Oncology deal royalty rate distribution, US$million - phase III stage
  • Figure 44: Oncology deal royalty rate distribution, US$million - regulatory stage
  • Figure 45: Summary median royalty rate by stage of development, 2009-2014
  • Figure 46: Top oncology deals by value since 2009
Show More
Pricing
Get Notified
Email me when related reports are published